WallStSmart

Fennec Pharmaceuticals Inc (FENC)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 1463% more annual revenue ($606.42M vs $38.79M). INSM leads profitability with a -2.1% profit margin vs -17.9%. INSM appears more attractively valued with a PEG of 1.09. INSM earns a higher WallStSmart Score of 39/100 (F).

FENC

Hold

36

out of 100

Grade: F

Growth: 6.3Profit: 2.0Value: 6.7Quality: 5.0

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

FENC1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
78.7%10/10

Revenue surging 78.7% year-over-year

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

FENC4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$250.00M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-10.1%2/10

ROE of -10.1% — below average capital efficiency

Profit MarginProfitability
-17.9%1/10

Currently unprofitable

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : FENC

The strongest argument for FENC centers on Revenue Growth. Revenue growth of 78.7% demonstrates continued momentum. PEG of 1.47 suggests the stock is reasonably priced for its growth.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : FENC

The primary concerns for FENC are EPS Growth, Market Cap, Return on Equity.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

FENC profiles as a hypergrowth stock while INSM is a turnaround play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

FENC is growing revenue faster at 78.7% — sustainability is the question.

FENC generates stronger free cash flow (1M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 36/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Fennec Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops candidate products for use in the treatment of cancer in the United States. The company is headquartered in Research Triangle Park, North Carolina.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?